SCHEMBL6573853

SCHEMBL6573853

CC(C)S(=O)(=O)NCC(C)(O)c1ccc(NCc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.48
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
HIF1A Q16665 1/20 0.43
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.41
GRIA4 P48058 4/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
GRIA2 P42262 1/20 0.40
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
NCOR2 Q9Y618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6563345 0.83 CYP2C19 (0.53) CYP2C19KMT2AGRIA4GRIA2
SCHEMBL6573861 0.82 CYP2C19 (0.47) CYP2C19CA1CA2CA12CA9
SCHEMBL5187225 0.81 GRIA4 (0.63) CYP2C19CA1CA2CA12CA9
SCHEMBL5187436 0.80 CYP2C19 (0.47) CYP2C19CA1CA2CA12CA9
SCHEMBL13255837 0.79 CYP2C19 (0.49) CYP2C19KMT2AGRIA4GRIA2
SCHEMBL13256290 0.79 CYP2C19 (0.49) CYP2C19KMT2AGRIA4GRIA2
SCHEMBL13566107 0.78 CA1 (0.45) CA1CA2CA12CA9HIF1A
SCHEMBL5188496 0.77 CYP2C19 (0.48) CYP2C19GRIA4
SCHEMBL14394435 0.77 CYP2C19 (0.48) CYP2C19CA1CA2CA9KMT2A
SCHEMBL5188470 0.76 GRIA4 (0.48) CYP2C19CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 CYP2C19 857/4885CA1 623/4885CA2 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.